European Journal of Pharmacology · Nov 17, 2026
Catalpol Prevents Ovariectomy-Induced Bone Loss Through DUSP6-Mediated Suppression of SMAD2/NFATc1 Signaling and Osteoclast Differentiation
By Wang Y, Wang L, Yu W et al.
Background Postmenopausal osteoporosis is characterized by estrogen deficiency-induced disruption of bone remodeling. Catalpol exerts bone-protective effects, but its direct molecular target and underlying mechanism remain incompletely understood. Objective To determine whether catalpol attenuates ovariectomy (OVX)-induced bone loss through dual-specificity phosphatase 6 (DUSP6)/SMAD family member 2 (SMAD2)/nuclear factor of activated T cells cytoplasmic 1 (NFATc1) signaling and to evaluate its effects on osteogenic differentiation. Methods OVX rats were treated with catalpol (5, 10, or 20 mg/kg) or alendronate for 12 weeks. Bone microarchitecture, bone remodeling, and osteoclast-related changes were assessed. In RAW264.7 cells, DUSP6 dependence was examined by knockdown and rescue experiments. Catalpol–DUSP6 interaction was evaluated by molecular docking, cellular thermal shift assay, and microscale thermophoresis (MST). Osteogenic differentiation was assessed in MC3T3-E1 cells. Results Catalpol improved trabecular microarchitecture, increased osteoblast-related histomorphometric parameters, and suppressed osteoclast formation in OVX rats. Catalpol increased DUSP6 expression and DUSP6–SMAD2 association, reduced SMAD2 phosphorylation, and inhibited NFATc1 nuclear accumulation. DUSP6 knockdown attenuated these effects, whereas DUSP6 restoration restored catalpol responsiveness. MST demonstrated direct catalpol binding to WT-DUSP6 (Kd = 3.617 μM), while mutation of predicted binding residues weakened the interaction (Kd = 48.12 μM). Catalpol also enhanced alkaline phosphatase-positive area, matrix mineralization, and osteogenic protein expression. Conclusion Catalpol attenuates OVX-induced bone loss through DUSP6-mediated suppression of SMAD2/NFATc1-dependent osteoclastogenesis and additionally promotes osteogenic differentiation in vitro.
doi.org/10.1016/j.ejphar.2026.179565PubMed 43044746Interventions